Effects of long-term continuous positive airway pressure on body composition and IGF1 by Münzer, T et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Effects of long-term continuous positive airway pressure on body
composition and IGF1
Münzer, T; Hegglin, A; Stannek, T; Schoch, O D; Korte, W; Büche, D; Schmid, C;
Hürny, C
Münzer, T; Hegglin, A; Stannek, T; Schoch, O D; Korte, W; Büche, D; Schmid, C; Hürny, C (2010). Effects of
long-term continuous positive airway pressure on body composition and IGF1. European Journal of Endocrinology,
162(4):695-704.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Endocrinology 2010, 162(4):695-704.
Münzer, T; Hegglin, A; Stannek, T; Schoch, O D; Korte, W; Büche, D; Schmid, C; Hürny, C (2010). Effects of
long-term continuous positive airway pressure on body composition and IGF1. European Journal of Endocrinology,
162(4):695-704.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Endocrinology 2010, 162(4):695-704.
 1 
Effects of Long Term CPAP on Body Composition and IGF-1 
MS EJE-09-0919.R1 
 
 
Thomas Münzer
1
, Andrea Hegglin
1
, Tobias Stannek
1
, Otto D. Schoch
2
, Wolfgang 
Korte
3
, Daniel Büche
4
, Christoph Schmid
5
 and Christoph Hürny
1 
 
 
 
 
1 
Geriatrische Klinik, Kompetenzzentrum Gesundheit und Alter, St. Gallen and 
Geriatric University Hospital, Bern 
2 
Multidisciplinary Sleep Center and Division
 
of Pulmonary Medicine Kantonsspital 
St. Gallen 
3 
Institute for Clinical Chemistry Kantonsspital St. Gallen 
4
 Bone Clinic Kantonsspital St. Gallen 
5
 Division of Endocrinology and Diabetes, Department of Internal Medicine, 
University Hospital, Zürich  
 
Switzerland 
 
 
 
 
 
Dr. Thomas Münzer MD 
Geriatrische Klinik 
Rorschacherstrasse 94 
9000 St. Gallen 
Switzerland 
P:+41 71 2438887 
F:+41 71 2438113 
thomas.muenzer@geriatrie-sg.ch 
 
Key Words: Growth hormone, hormone secretion, sleep apnea, body composition, 
gender 
 
Word Counts: Abstract: 246; Article: 4151 
Tables: 2 
Figures: 1 
 
 
Running title: Long term effects of CPAP on body composition and IGF-1 
 
Page 1 of 25
 Accepted Preprint first posted on 29 January 2010 as Manuscript EJE-09-0919
 Copyright © 2010 European Society of Endocrinology.
 2 
 
Abstract 
 
Objective: To investigate long term effects of nasal continuous positive airway 
pressure ventilation (CPAP) in patients with obstructive sleep apnea syndrome on 
body composition (BC) and IGF-1. Design: Observational study. Subjects: 78 (11f, 
67m) OSAS patients compliant with CPAP (age 51±1.1 years). We assessed body 
mass index (BMI), total body mass (TBM), body fat (TBF) (kg) and lean body mass 
(LBM) (kg), abdominal subcutaneous (SC) and visceral (V) fat (cm
2
), waist 
circumference (WC, cm) by MRI and IGF-1 (ng/ml) before and after 7.8±1.3 months 
of CPAP use of an average of 5.9±1.2 h. 
Results: Women had a higher BMI, WC, TBM, TBF and more SCfat. Men had a 
higher LBM and more Vfat. CPAP increased WC (+2.8±9.6 cm (p=0.02), LBM 
2.2±0.5 kg (p=0.006) but not IGF-1. In men CPAP increased BMI (0.5±0.2 kg/m
2
 
(p=0.02), WC 1.7±6.9 cm (p=0.002), TBM 1.7±0.4 kg (p=0.0001), LBM 1.5±0.4 kg 
(p=0.0003) SCfat (12.9±5.1 cm
2
 (p=0.02) and IGF-1 (13.6±4.2 ng/ml (p=0.002). 
Compliance with CPAP increased LBM in men aged <60 but not in those aged >60, 
and IGF-1 increased in men aged 40-60 only. 
Conclusions: Long term CPAP increased LBM in both sexes and IGF-1 in men while 
fat mass remained unchanged suggesting a sexually dimorphic response of IGF-1 to 
CPAP. The role of the GH axis activity and age to this response is unclear. The 
metabolic consequences of changes in LBM remain to be determined. Future studies 
on the effects of CPAP on body composition should include LBM as an outcome.
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Introduction 
Obstructive sleep apnea syndrome (OSAS) is defined as repetitive decreases or 
cessations of airflow during sleep 
1
 is associated with a wide array of cardiovascular 
2
 
and metabolic risks 
3, 4
 and therefore linked to an elevated cardiovascular morbidity 
and mortality. Interestingly, part of the risk profile appears to be shared with patients 
suffering from adult growth hormone deficiency syndrome 
5
. Indeed, In addition 
OSAS has been associated with significant decreases in serum IGF-1 levels 
6
 and 
several metabolic disorders and alterations in body composition such as visceral 
obesity 
7
. One possible explanation for the underlying mechanism in OSAS patients is 
the relative insensitivity of GHRH-induced GH response and a delayed IGF-1 
synthesis after GH injection in untreated disease 
8
. The physiologic release of GH in 
healthy humans is stimulated by GHRH as a function of sleep depth 
9
. Thus CPAP 
therapy may lead to a restoration of the GH axis activity to a more physiological 
pattern and consecutively affect body composition 
6, 10-12
. Adipose tissue has been 
associated with most of the metabolic burden associated with OSAS 
7, 13, 14
 and short 
term CPAP reduces visceral fat 
15
. However to date no study has examined the effects 
of CPAP ventilation on lean body mass, despite potential beneficial effects of such 
changes on body function. During normal aging mean GH secretion decreases mainly 
due to diminished amplitude of spontaneous GH peaks, whereas peak frequency 
usually remains unchanged 
16
. Aging also is associated with decreased serum IGF-I 
levels which correlate well with GH secretory peaks in both, women and men 
17-19
. 
Several studies have demonstrated a significant relationship between a reduction of 
slow wave sleep, decreased GH secretion rate and peak amplitude in healthy aged 
individuals 
16, 20
, and GH releasing drugs can normalize sleep 
21
. Taken together, these 
data suggest that in addition to normal aging, sleep disturbances such as sleep apnea 
may substantially affect GH secretion and action and thereby have additional impact 
on the potential effects of CPAP treatment.  
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Several studies have reported a sexual dimorphic interaction of GH axis activation 
with sleep 
22-24
, and GH administration to healthy old persons 
25, 26
 or GH therapy in 
patients with adult GH deficiency syndrome 
27
 both revealed that changes in lean body 
mass or adipose tissue depended on sex. 
Based on the above findings, we hypothesized that long-term CPAP therapy would 
increase serum IGF-1 levels in patients with OSAS and that these changes would have 
been affected by the sex and the age of the patients. In addition, we examined the 
effects of CPAP on body composition including total and regional fat tissue and LBM. 
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Patient Selection 
Inclusion and Exclusion Criteria 
All women and men over 18 years who were admitted as outpatients to the 
Kantonsspital St. Gallen Interdisciplilnary Center for Sleep Medicine between 01-01-
2003 and 12-31-2005 for the evaluation of possible OSAS were invited to participate. 
Patients were usually referred by primary care physicians, pneumonologists, 
neurologists and ENT- specialists. Patients with diabetes and hypercholesterolemia 
were included if on stable (oral) medication. There was no change in medication 
throughout the study period. Patients who participated in any other clinical study in 
the last six months prior to this protocol were excluded. In addition, we excluded 
women and men who were not able to complete German questionnaires without 
language support by their family members. Patients with pituitary disease, untreated 
thyroid disease, medication known to interfere with the GH axis and patients with 
elective surgery (such as gastric banding or hip replacement) within 6 months after 
enrolment were also not eligible. All patients were asked to keep their diets and their 
level of physical activity constant during the study period. Written informed consent 
was obtained from all participants. The protocol had been approved by the St. Gallen 
ethics committee. 
Patients with possible OSAS were scheduled for an outpatient visit with one of the 
physicians in the sleep center. Prior to this appointment, all patients routinely 
completed a set of questionnaires. Covered domains were: socio-demographic data, 
assessment of smoking status and alcohol use, a validated German version of the 
Epworth Sleepiness Scale 
28
 and the Stanford Sleep Disorders Questionnaire 
29
. During 
the appointment, each patient had a complete medical history to assess co-morbidities 
30
 such as hypertension, coronary heart disease, diabetes, hypercholesterolemia, and 
current medication. Physical examination included inspection of the oropharynx, 
auscultation of lungs and heart, and abdominal palpation, followed by a brief 
neurological exam. Patients who, based on clinical judgment and the results of these 
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screening questionnaires had a high likelihood to have OSAS were then scheduled for 
polysomnography (PSG). In the evening preceding PSG, patients were admitted to the 
sleep center. They were then asked to participate in the study. In the morning after the 
sleep study, after an overnight fast, blood samples for baseline measurements 
including IGF-1 were drawn, independent of the result of the sleep study. Patients 
with OSAS who agreed to begin with CPAP were scheduled for baseline body 
composition before or during a two-week time period after initiation of CPAP therapy. 
Patients received an instruction in nasal CPAP ventilation followed by home CPAP. 
Monitoring of hours of operation of the CPAP machine was used as a measure of 
compliance. After at least 6 months of CPAP ventilation, all baseline examinations 
were repeated. 
 
Materials and Methods 
Polysomnography 
Polysomnography data were recorded with a commercially available monitoring 
system (Mepal, MAP Medizin-Technologie, Martinsried, Germany). In the evening 
preceding the sleep study, each participant was offered a standardized meal at 18.00h. 
Lights were turned off at 22.00h. Minimum recording time was 6 hours in order to 
meet diagnostic standards. All sleep studies were analyzed by an experienced 
physician. Respiration was traced with nasal pressure prongs and by piezoelectrical 
thoracic and abdominal effort bands. Main outcome variables for the diagnosis of 
OSAS were: apnea-hypopnea index (AHI) defined as the number of apneas (>80% 
reduction of the flow signal) and hypopneas (>50% reduction of the flow signal) per 
hour of sleep monitored and the desaturation index (DESI) defined as the hourly rate 
of episodes of arterial oxygen desaturations >3% of the stable baseline. The severity of 
sleep apnea was graded as mild (5-15 events per hour) moderate (16-30 events per 
hour) and severe (>30 events per hour) 
1
. Depending on the results of this analysis the 
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patients were advised to commence with CPAP instruction followed by continuous 
home ventilation. 
 
Nasal CPAP-Ventilation and Assessment of Compliance 
Patients who were eligible for ventilation were instructed by trained nurses in the 
sleep center. Effectiveness of ventilation was monitored by changes in clinical 
symptoms, nocturnal oxygen saturation SaO2 recordings and an automated CPAP-
titration device (Sullivan Autoset T). After a period of 3 overnight stays in the unit, 
patients were discharged for home ventilation. As an estimate of compliance with the 
CPAP machine over the entire study period we recorded the mean hours of operation 
per night during 6 months of CPAP use. Ambulatory overnight oximetry (Konica-
Minolta Pulsox 3, Anandic, Switzerland) was used to measure changes of oxygen 
saturation while ventilated at home. In addition, one single experienced 
pneumonologist (ODS) reviewed all patient charts and oximetry results. Based on 
clinical follow-up information, overnight oximetry data and chart information, patients 
were graded into two categories: non-compliant, well-compliant. We defined an 
average of ≥4 hours of CPAP use per night as a minimum requirement to classify a 
patient as compliant 
31
.  
 
Clinical Assessment of Body Composition 
Weight was measured to the nearest 0.1 kg on a calibrated scale and height was 
determined using a wall-mounted stadiometer. Body mass index (BMI) was calculated 
as the weight divided by the square of height (kg/m
2
).  
 
Imaging Studies for the Assessment of Body Composition 
Each study participant had a dual X-ray absorptiometry (DEXA) determination of 
LBM and total and relative fat mass. DEXA assessment was performed by one single 
experienced technician at the Kantonsspital St. Gallen Bone Clinic with a 
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commercially available scanner (Lunar DPX-NT, Lunar, General Electrics Healthcare, 
Munich Germany). We used the scanner-installed software package (Encore Version 
6.7). The subjects were measured in light clothing. The scanner was calibrated every 
morning and three times a week; a bone phantom scan was used to determine scan 
quality. Internal calibration demonstrated a CV of 0.16%. This method has been 
shown to precisely assess body composition in several research settings 
32, 33
. Patients 
underwent magnetic resonance imaging (MRI) at the level of L4/5 for the assessment 
of abdominal subcutaneous (sc) and visceral fat areas. Abdominal MRI examinations 
were performed on a 1.5 T clinical imaging system (Symphony, Siemens Munich 
Germany, software version Syngo MR2004A4VA25A). Patients were scanned in the 
non-fasting state in supine position using breath holding technique and a T1, flash-2 D 
sequence set to optimize fat bright signal versus intermediate to dark signal adjacent 
tissue. Image matrix size was adapted to scan the greatest area possible. Slice 
thickness was 8 mm with an interslice gap of 100%. Images were analysed on a PC 
using ImageJ an NIH-developed analysing software (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 
1997-2006) as described previously 
34
. 
 
Serum IGF-1 
After the sleep study and at follow-up, after an overnight fast, blood samples were 
drawn from an antecubital vein. After centrifugation, serum aliquots were stored at –
80°C, and then sent to the Research Laboratory of the Division of Endocrinology at 
the University of Zürich for measurements of insulin-like growth factor-1
 
(IGF-1) 
levels. IGF-binding proteins were removed by acid Sep-Pak
®
 chromatography
 
according to the instructions of the supplier (Waters Associates, Milford, MA),
 
and 
IGF-1 was determined by RIA 
35, 36
. All samples were analysed in a single batch by a 
technician who was not aware of any study data. 
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Data management and statistical analyses 
Analyses were done with Stata (Stata, Stata Corp. 2005. Stata Statistical Software: 
Release 9. College Station, TX). Summary statistics are described as means, medians 
and standard errors of the mean (SE). Baseline associations of were calculated by 
simple linear regression. We first analysed overall changes in the respective outcome 
parameters, followed by analyses for changes in non-compliant and compliant patients 
respectively. To examine possible sex and age effects, the compliant group was 
grouped by sex, and men were categorized based on the age at study entry (≤40, 40-
60, >60 years). Subsequent statistical analyses were performed in each age-category 
separately. Differences between categorical variables within each age or sex group 
were assessed by Chi
2
 tests and differences between continuous variables were 
calculated with Mann-Whitney tests or t-tests where appropriate. In addition, we 
applied ANOVA to detect possible differences between age categories at baseline. 
Contributions of baseline factors to changes of outcome variables of interest were 
entered into a stepwise linear regression model. A p-value of less than 0.05 was 
considered as significant. 
 
Results 
Patients (Figure 1, Tables 1 and 2) 
Out of 566 patients screened for participation, 101 patients were excluded due to 
language barriers. 198 patients did not give informed consent for personal and work-
related reasons (difficulty to leave the job for additional study appointments). Non-
consenters and consenters did not differ by age, sex, BMI, smoking status and socio-
demographic data; however, consenters more often reported alcohol use (215/260, 
82.7% vs. 143/192, 74.5%, p=0.03) and had a slightly higher mean ESS score 
(11.3±4.4 vs. 10.6±4.8, p=0.03) (data not shown). Using disease categories provided 
in the Charlson Comorbidity-Index 
30
 we found an increased prevalence of chronic 
obstructive pulmonary disease in patients > 60 years and no additional associations of 
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age with other chronic diseases. Eight patients with diabetes on regular oral 
medication (sulfonylurea or metformin) were included. Patients were equally 
distributed between severity and age categories (Chi-Square test p=0.4, data not 
shown). We here report data on changes in body composition in 78 patients (11 
women, 67 men) who were compliant and on 35 patients who were non-compliant 
with ventilation for a period of at least 6 months. For 73 of them (56 compliant) 
complete data sets of serum IGF-1 were available. 
 
Baseline Characteristics of Study Population (Table 1) 
At baseline, compliant and non-compliant patients were not statistically different 
regarding age, WC, BMI, TBM, LBM, TFM, SC fat, V fat and IGF-1 levels and, 
compliance did not differ between age categories (data not shown). However, non-
compliant patients had a lower apnea-hypopnea-index (difference -13.8±5.7, p=0.02). 
We studied 11 compliant women and 5 women who were not compliant with CPAP 
use. Using Chi-Square analysis women were evenly distributed among age and 
compliance groups (p=0.41).  
Compliant woman and men did not differ by age, TBM, V fat and baseline IGF-1. In 
contrast women had a higher BMI (+5.0±1.6, p=0.003), a higher waist circumference 
(+8.6±2.8 cm, p=0.004 ), less LBM (-12.3±2.4 kg, p=0.000001), more total body fat 
(+21.4 kg±3.3 kg, p=0.000001), more SC fat (+188.9±26 cm
2
, p=0.000001).  
Baseline Serum IGF-1 (Table 1) 
There was no sex difference between serum IGF-1 levels at baseline and at follow up. 
Thus, IGF-1 data were pooled for analysis. IGF-1 levels tended to be higher in 
noncompliant patients but levels did not differ among age or compliance groups at 
baseline, and we found no correlation of age with IGF-1 (data not shown). 
 
Baseline Associations of IGF-1 and LBM with OSAS severity  
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At baseline we found no significant correlations of IGF-1 with TBM, TBF, LBM or 
AHI, neither overall nor across or within age categories. In addition, we found no 
associations of LBM with AHI or with IGF-1 overall or across age categories (data not 
shown). 
 
Effects of CPAP on body composition and IGF-1 levels in non-compliant patients 
(Table 2) 
Patients underwent effective (nightly usage >4 hours, mean 5.5±1.2 h) CPAP 
ventilation therapy over a period of 7.8±1.3 months. In contrast non-compliant 
patients used the machine during an average of 2.4±0.2 h per night (p=0.00001). In 
non-compliant patients, waist circumference increased by +2.7±7.3 cm (p=0.002) and 
BMI by 0.5±0.3 kg/m
2 
(p=0.004). In addition TBM increased (+1.8±0.7 kg, p=0.01), 
LBM (1.3±0.7 kg, p=0.07) and TFM (+0.6±0.8 kg, p= 0.5) remained unchanged. 
Abdominal SC fat increased by 19±9 cm
2 
(p= 0.047) and V fat by 12.3±15.6 cm
2 
(p=0.4). Serum IGF-1 levels increased by +3.2±8.4 ng/ml (p=0.7). 
 
Effects of CPAP on Body Composition and Serum IGF-1 Levels in Compliant 
Patients by Sex (Table 2) 
After almost 8 months of CPAP we found overall increases in BMI (0.5±0.2 kg/m
2
, 
p=0.006), waist circumference (+1.9 ±0.6 cm, p=0.002) and of SC fat (+15±5 cm
2
, 
p=0.008). In addition TBM (+1.7±0.4 kg p=0.00001), LBM (+1.6±2.5 kg p=0.00001) 
and serum IGF-1 (+10.6±4 ng/ml, p=0.01) increased significantly and there were no 
changes in TBF, V fat or BMI respectively. In compliant women CPAP increased WC 
(+2.8 ±9.6 cm, p=0.02) and LBM (+2.2 ±0.5 kg, p=0.006) only. In compliant men 
CPAP affected BMI (0.5±0.2 kg/m
2
, p=0.02), WC (1.7±0.7 cm, p=0.02), TBM 
(1.7±0.4 kg, p=0.001) and LBM (1.5±0.4 kg, p=0.003). Furthermore SCfat (+12.9±5.1 
cm
2
, p=0.02) and IGF-1 (+13.6±4.2 ng/ml, p=0.002) increased after CPAP. 
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Effects of nCPAP on Body Composition and Serum IGF-1 Levels in Compliant 
Men by Age 
In men<40 years, BMI (+1.0±0.4 kg/m
2
, p=0.02), TBM (+3.4±1.2 kg p=0.02), LBM 
(+3.0±1.0 kg p=0.02) but not IGF-1 (+23.0±12.3 ng/ml p=0.1) increased significantly 
and there was a trend towards an increase in WC (p=0.07). In patients aged 40-60 
years TBM (+1.0±0.5 kg p=0.03), LBM (+1.0±0.4 kg p=0.02) and IGF-1 (+12.6±5.3 
ng/ml, p=0.02) increased significantly. In men aged 60 and older we found a 
significant increase in TBM (+2.3±0.8 kg p=0.01) a trend towards an increase in BMI 
but no changes in other measures of body composition or IGF-1 levels. 
 
 
Stepwise Multiple Linear Regression of Changes in IGF-1 and LBM in 
Compliant Men 
Using stepwise multiple regression analysis in men with changes in IGF-1 (Model 1) 
or changes in LBM (Model 2) as dependent variables and changes in body 
composition, age at baseline and hours of ventilation as independent variables, we 
found no statistically significant model. However hours of ventilation best predicted 
changes in LBM and IGF-1 respectively. 
 
Discussion 
In this nonrandomized prospective trial in patients diagnosed with sleep apnea 
syndrome we found that compliance with CPAP over a period of eight months 
significantly increased LBM in woman and men and that IGF-1 increased in men only. 
Overall we observed small increases in WC and SC fat in all groups despite 
compliance with ventilation. In contrast in non-compliant patients LBM remained 
unchanged. Serum IGF-1 levels increased in compliant men but not in women or in 
non-compliant patients. 
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Several groups have reported associations of OSAS with fat tissue as a 
dependent 
7, 14, 37
 or an independent 
38, 39
 metabolic risk factor. A previous study 
reported reductions of V fat areas after three months of CPAP ventilation in a cohort 
of men aged 50 with a very high AHI 
15
. We found small increases in abdominal SC 
fat and WC but not in V fat using a different imaging method in a mixed patient 
population with a wider age range treated over a longer time period. Nevertheless, 
increases in waist circumference of 1.9 cm overall in association with respective 
changes in SC fat warrant further discussion. 
Anthropometric measures of obesity often predict the prevalence of sleep 
apnea. Especially WC is a reliable predictor of OSAS severity 
40, 41
 and a clinically 
well known parameter to assess the metabolic syndrome 
42
. Therefore, treatment with 
CPAP could be associated with a reduction in WC. Contrary to such an expectation, 
we found significant increases in SC fat and waist and very small increases in total 
body fat while total body remained almost constant over the 8 months of ventilation. If 
such changes impact upon the metabolic burden of OSAS patients is currently unclear 
since several alterations associated with this disease are independent of fat tissues 
12, 39
. 
Apparently, the effects of CPAP on body composition in OSAS are distinct from 
effects of GH in GHD, where TBF is usually decreased, in addition to an increase in 
IGF-1 and LBM. 
 Although fat tissue is of clinical importance in patients with sleep apnea, the 
effects of CPAP use on LBM have not been examined. In man, the impact of muscle 
mass and exercise on glucose uptake has been known for a long time 
43
, and numerous 
studies have confirmed the roles of skeletal muscle, its oxidative capacity and energy 
expenditure on insulin sensitivity, strongly supporting the role of LBM in glucose 
metabolism. We have recently reported that CPAP ventilation significantly improved 
maximal exercise capacity and heart rate recovery in our patients 
44
, a finding that is in 
line with an earlier report on effects of 4 weeks of CPAP treatment on endurance 
exercise performance 
45
. Taken together, such data suggest that the increases in LBM 
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and the improvement in VO2 max both reflect changes with the potential to increase 
exercise performance and to decrease the metabolic and cardiovascular risks of OSAS 
patients. 
 The mechanisms by which CPAP affects LBM are currently unknown. First, 
ventilated patients report less daytime sleepiness and more vitality 
46 
which may 
impact upon their level of physical activity and protect against the disease 
47
. In 
addition, physical activity augments GH axis activity in young and to a lesser extent in 
older persons 
48, 49
. Thus, exercise-induced increases in GH axis activity may have 
additional beneficial effects on LBM. In order to control for such an effect we have 
asked our patients to not change their levels of exercise or their diets during the study 
period. However our protocol did not record daily activities or diets, which seemed 
not feasible for such a long study period and the clinical design. Another factor 
contributing to changes in body composition after CPAP use is energy expenditure 
(EE). Several studies have demonstrated that REE is closely associated with OSAS 
and disease severity respectively 
50, 51
 and one previous report demonstrated that EE is 
increased during sleep in OSAS patients and CPAP decreases EE and by this 
mechanism induces an body weight 
52
 and possibly also LBM. 
  In contrast to healthy young or older individuals we found no 
significant correlations of IGF-1 with measures of body fat 
53
 or age 
19
 in our patients 
at baseline. These findings suggest a disruption of the GH-IGF-1 axis activity based 
on a change in regular sleep pattern with this disease 
54
 or could be an effect of the 
small sample size. Although one month of sham ventilation induced elevated IGF-1 
levels 
55
 normalisation of sleep pattern induces a restoration of the GH axis activity. 
Three days of CPAP ventilation induced increases in GH 
10
 and, IGF-1 levels 
increased after three months of CPAP 
6
. The latter group also found an age-dependent 
response of IGF-1 to CPAP 
6
. Given the fact that normal aging is associated with a 
decrease in GH secretion 
17
 the above and our results suggest that the IGF-1 response 
to 8 months of CPAP may also be attenuated with advanced age. Similarly, we 
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observed increases in IGF-1 and LBM in middle aged but not in older or younger men. 
The latter finding can be explained by the small number of men studied. Nevertheless 
such a pattern is congruent with a reduced response in LBM after GH given to healthy 
older individuals 
56
 when compared to young patients with adult GH deficiency 
syndrome 
57-59
. 
Serum IGF-1 concentrations after CPAP remained unchanged in our women. 
While these results should be interpreted with some caution due to the small sample 
size, current findings suggest that GHRH impairs sleep in women 
22
 and the GH 
secretagogue ghrelin improves sleep in young and older men 
60, 61
 but not in women 
suggesting a sexually dimorphic response of sleep to hormone administration. While 
CPAP is known to decrease Ghrelin in men 
62
, data on women are missing. Otherwise 
normalization of sleep pattern by CPAP might impact upon GH secretion and IGF-1 
synthesis in women and men differently. Based on these observations our data suggest 
that long term CPAP activates the GH axis and that such changes are gender 
dependent.  
Our study has several limitations. First, our design did not allow for a true 
control group. Thus the effects of CPAP on groups are comparable only to a limited 
extend and the current design allows hypothesis generation rather than hypothesis 
testing. This is especially true for the hypothesis of a possible dose-response 
relationship between CPAP and changes in body composition since the primary 
treatment goal of CPAP is elimination of obstructive events. Nevertheless our 
regression model suggested that the duration of ventilation is a potential predictor for 
changes in LBM. In addition we did not record the menopausal status of our women. 
Postmenopausal status is associated with an increased prevalence of sleep disordered 
breathing 
63, 64
 and circulating progesterone protects against dilation of the upper 
airway muscles 
65
. Women in our study were evenly distributed among age and 
compliance groups which attenuated the effect of menopause on our results. 
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We were also not able to randomize patients into a placebo ventilation group although 
such studies have demonstrated an improvement in function 
66
, endocrine axis activity 
55
 or control of diabetes 
67
. Given the study duration of at least six months and the high 
risk for cardiac events in untreated patients 
68
 it seemed unethical to not offer 
treatment for such a long period. Second, we were able to recruit only a small numbers 
of patients into the respective study groups. This might have affected our results. In 
addition, we were not able to demonstrate direct effects of CPAP ventilation on GH 
axis activity by frequent GH sampling. Given the diminished GH response to 
stimulation in untreated patients with OSAS 
8
 it seems comprehensible that ventilation 
would induce a more ordered 24 h GH secretion. Our study was primarily focused on 
changes in body composition. We thus did not record changes in other clinically 
important measures such as blood pressure which has been shown to decrease in 
several trials 
69-71
. Finally, using a pre-post design, we were able to detect changes 
within specific age categories only. This approach does not allow for inferring a direct 
effect of age on the main outcome variable. To approach such an effect a regression 
model with a larger number of data points would have been more appropriate. 
However, we think that our study allows to hypothesise that CPAP treatment affects 
LBM by several mechanisms, one being the restoration of the GH axis activity and, 
furthermore, that this effect might be influenced by the age of the patients. 
 In summary, the results of our study suggest that an average of eight months 
of CPAP ventilation in patients with newly diagnosed OSAS significantly increased 
LBM in women and men. The observed changes in IGF-1 suggest a sexual dimorphic 
response pattern of GH secretion after CPAP therapy. Future studies on body 
composition in OSAS patients should include LBM as a clinical outcome parameter. 
Given the increasing prevalence of sleep disordered breathing in a growing number of 
older persons 
64, 72
 and the small number of women studied with this disease additional 
trials on the effects of CPAP ventilation in women or in persons with advanced age 
are warranted. 
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Figure Legends 
 
Figure 1. Study Flow 
 
Page 22 of 25
Referral for possible OSAS
N=566
Eligible
N=465
Not eligible
N=101
Informed Consent
N=267
Indication for ventilation
N=172
Started ventilation
N=161
Completed ventilation
N=113
Not ventilated
N=11
Did not complete
ventilation
N=48
No informed consent
N=198
Indication for ventilation
N=95
Started ventilation
N=95
No indication
for ventilation
N=95
Not ventilated
N=0
No indication
for ventilation
N=103
Compliant with ventilation
N=78
Non-Compliant with 
ventilation
N=35
Complete sets of 
IGF-1
N=56
Complete sets of 
IGF-1
N=17
Page 23 of 25
Table 1. Baseline Characteristics of 35 Non-Compliant and of 78 Patients Compliant with CPAP (Means ± SE)  
           
 Non-Compliant Compliant Women Compliant Men Sex Difference 
 
All 
(N=35) Range 
Mean 
(N=11) Range 
Mean 
(N=67) Range P 
Age (years) 52.1 19.8 76.9 51.2 37.6 70.7 50.8 27.2 77.5 0.5 
AHI1 32.5a 8.4 109.0 46.3 7.5 95.7 49.4 7.1 109.0 0.1 
BMI2 30.4 23.8 39.7 30.9 26.2 43.4 30.0 22.1 41.7 0.004 
Waist Circumferene (cm) 103.9 88.8 127.4 104.1 93.5 119.0 102.7 87.3 120.6 0.004 
Total Body Mass (kg) by DEXA3 89.1 71.7 126.2 90.5 71.7 114.6 89.4 70.8 130.8 0.0003 
Lean Body Mass (kg) by DEXA 55.6 38.5 75.9 56.7 39.7 50.7 58.3 45.4 75.2 0.000001 
Total Fat Mass (kg) by DEXA 30.5 20.9 50.4 49.5 29.4 61.5 28.1 15.5 55.6 0.000001 
Abdominal subcutaneous fat (cm2) 243.3 137.9 405.3 415 268.6 546.3 226 124.0 516.0 0.000001 
Abdominal visceral fat by MRI 
(cm2) 211.3 72.1 367.4 163 69.3 273.1 210 60.2 443.3 0.1 
IGF-1 (ng/ml) 130.5 67.0 300.0 124.0 56.0 235.0 115.1 44.0 241.0 0.6 
Average CPAP use per night 2.5b 0.2 3.9 6.0 4.0 8.0 5.9 4.0 8.8 0.1 
           
1 Apnea-Hypopnea Index           
2 Body Mass Index           
3 Dual Energy X-Ray Absorptiometry          
a p=0.02, b p=0.0001           
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Table 2. Overall Changes (Means±SE) in Body Composition and Serum IGF-1 Levels after 6 Months of CPAP Ventilation in Non-Compliant Patients and in Compliant 
Women an Men with Obstructive Sleep Apnea Syndrome 
                     
  Non-Compliant  Compliant Compliant Women Compliant Men 
  N=35 SE CI P* N=78 SE CI P* N=11 SE CI P* N=67 SE CI P* 
BMI
1
 0.5 0.3 0.1 1.0 0.04 0.51 0.18 0.15 0.86 0.006 0.6 0.4 -0.2 1.5 0.10 0.5 0.2 0.1 0.9 0.02 
Waist Circumferene (cm) 2.7 7.3 1.2 4.3 0.002 1.90 0.59 0.72 3.09 0.002 2.8 9.6 6.1 50.1 0.02 1.7 0.7 3.0 31.0 0.02 
Total Body Mass (kg) by DEXA
2
 1.8 0.7 0.4 3.2 0.013 1.70 0.38 0.95 2.50 0.00001 1.7 1.3 -1.4 4.8 0.22 1.7 0.4 0.9 2.5 0.0001 
Lean Body Mass (kg) by DEXA 1.3 0.7 -0.1 2.8 0.1 1.59 0.34 0.91 2.28 0.00001 2.2 0.5 0.9 3.6 0.006 1.5 0.4 0.7 2.3 0.0003 
Total Fat Mass (kg) by DEXA 0.6 0.8 -0.1 2.2 0.5 0.2 0.3 -0.5 0.9 0.6 -0.4 1.0 -2.8 2.0 0.68 0.3 0.4 -0.5 1.0 0.48 
Abdominal subcutaneous fat (cm
2
) 19.3 9.0 8.3 41.5 0.047 15.05 5.45 4.07 26.03 0.008 24.4 2.0 
-
20.8 69.6 0.2 12.9 5.1 25.3 23.4 0.02 
Abdominal visceral fat by MRI (cm
2
) 12.3 15.2 
-
21.1 45.7 0.4 9.2 8.0 -6.9 25.4 0.2 16 1.3 
-
16.0 47.1 0.29 7.8 9.3 
-
11.2 26.8 0.41 
IGF-1 (ng/ml) 3.2 8.4 
-
14.8 21.2 0.7 10.6 4.1 2.4 18.8 0.01 -4.8 12.2 
-
33.1 23.3 0.7 13.6 4.2 5.1 22.0 0.002 
                     
* P for paired T-test                     
1
 Body Mass Index                     
2
 Dual Energy X-Ray Absorptiometry                     
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